drugset / Trial / NCT04722523
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Phase 1
Recruiting
40 enrolled
Memorial Sloan Kettering Cancer Center
Regeneron Pharmaceuticals · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer, and whether receiving this combination treatment before surgery may allow participants to forgo the standard radiation treatment after surgery.
Timeline
- Start
- 2021-01-20
- Primary completion
- 2026-06-20
- Completion
- 2026-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | — |
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 90 mg/m2 | — |